Table 2.
Study | Test Model | Nociceptive State | Vehicle | Species Sex (M/F) | Effect of APAP | PO mg/kg | IP/SC/IPLT mg/kg | IV mg/kg | IT µg | ICV µg | Reference | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1. | ATP-sensitive K+ channels and μ-opioid receptors in antinociceptive synergism of APAP-tapentadol | Formalin test | Formalin | Saline | Mice/M | Decreased behavior Dose dependent |
56–562 | Zapata-Morales et al 2018106 | ||||
2. | Synthesis and antinociceptive evaluation of bioisosteres and hybrids of naproxen, ibuprofen and APAP | Formalin test | Formalin | Saline | Rat/M | Decreased behavior Phase 2 |
0.6–3.2 | González-Trujano et al 2018157 | ||||
4. | Enhanced analgesic effects of nefopam with APAP | Writhing test | Acetic acid | Saline | Mice/M | Decreased behavior Dose dependent |
42–168 | Li et al 2018107 | ||||
5. | APAP relieves inflammatory pain through CB1 in rostral ventromedial medulla | Von Frey | ITSP, extract IPLT zymosan | Saline | Mice/M | Increased threshold Dose dependent |
30–300 | Klinger-Gratz et al 201767 | ||||
7. | Supraspinal TRPV1 desensitization induced by ICVT resiniferatoxin | Tail flick Formalin test | Resiniferatoxin agonist, hind paw) | Propylene glycol | Mice/M | Increased latency Decreased behavior |
100 or 300 | Fukushima et al 2017108 | ||||
8. | Imidazoline receptor and APAP schedule-controlled responses | Von Frey Thermal | Freund’s adjuvant | 20% DMSO and saline | Rat/M | Increased threshold/latency Dose dependent |
56–178 | Siemian et al 2016109 | ||||
9. | Modulating 5-HT system on the analgesic action of APAP in mice | Formalin test | Formalin | N/A | Mice/M | Decreased behavior Phase 1/2 |
200 | Karandikar et al 2016110 | ||||
10. | Antinociceptive effects of sinomenine in postoperative pain | Von Frey | Incisional surgery model (Brennan) | N/A | Rat/M | Increased threshold Dose dependent |
30–180 | Zhu et al 201669 | ||||
11. | Acetaminophen interacts with morphine and tramadol analgesia for the treatment of neuropathic pain | Von Frey | Carrag paw | Saline | Rat/M | Increased threshold Dose dependent |
20–1000 | Shinozaki et al 2015104 | ||||
12. | Supra-spinal FAAH required for APAP analgesia | Hot plate Von Frey | Carrag paw | Saline | Mice/M | Increased latency/threshold | 200 | Dalmann et al 201590 | ||||
13. | Antinociception by MT(2) melatonin receptor partial agonists | Hot plate | MT(2) melatonin receptor partial agonists | 70% dimethyl and 30% saline | Rat/M | Normalized threshold | 200 | López-Canul et al 2015158 | ||||
14. | Synergy of pregabalin-APAP in somatic/visceral pain | Writhing test | Acetic acid | Saline | Mice/M | Decreased behavior | 200 | Mititelu et al 2014101 | ||||
15. | Adamantyl analogues of APAP as potent analgesic drugs via inhibition of TRPA1 | Visceral pain | Acetic acid (IP, 2%) | N/A | Mice/M | Decreased behavior Dose dependent |
100–200 | Fresno et al 2014112 | ||||
16. | Cav3.2 calcium channels in supra- spinal APAP effect | Formalin test | Formalin | Saline | Mice/M | Decreased behavior | 200 | Kerckhove et al 201470 | ||||
17. | Arsenic decreases activity of APAP. Involvement of 5-HT and CB receptors | Formalin test | Formalin | Saline | Rat/M | Decreased behavior phase 1 | 400 | Vijayakaran et al 201471 | ||||
18. | APAP involves spinal serotonin 5-HT7 and adenosine A1 receptors, and peripheral adenosine A1 receptors | Formalin test | Formalin | Saline | Mice/M | Decreased behavior Phase 2 | 300 | Liu et al 2013120 | ||||
19. | Naltrexone did not change synergism between APAP and tramadol | Writhing test | Acetic acid | Saline | Mice/M | Decreased behavior Dose dependent |
4.0 | Miranda et al, 2012121 | ||||
20. | APAP-induced analgesic and antihyperalgesic effects by 5-HT pathways and spinal 5-HT7 receptors | Tail flick | Plantar incision | 20:1:1:78 mixture of DMSO: ethanol: Tween saline | Mice/M | Increased latency Dose dependent |
200–600 | Dogrul et al 201272 | ||||
21. | Caffeine inhibits APAP antinociception by spinal adenosine A1 receptors | Formalin test | Formalin | 20% DMSO | Mice/M | Decreased behavior phase 2 Dose dependent |
100–300 | Sawynok and Reid 2011123 | ||||
22. | Systematic evaluation of nefopam–APAP combination in rodent models of antinociception | Writhing test | Acetic acid | 1% Tween 80 and saline | Mice/M | Decreased behavior Dose dependent |
25–200 | Girard et al 2011159 | ||||
Formalin test | Formalin | 1% Tween 80 and saline | Mice/M | Decreased behavior Dose dependent |
100–600 | |||||||
Hot plate | Carrag in hind paw | 1% Tween 80 and saline | Rat/M | Normalized threshold | 300–600 | |||||||
23. | Ondansetron does not block APAP-induced analgesia | Von Frey Hot plate | Fracture pain model | N/A | Mice/M | Increased threshold/Latency | 300 | Minville et al 2011113 | ||||
24. | Synergy of APAP and oxcarbazepine | Paw pressure | Carrag hind paw | Tween 80 and saline | Rat/M | Increased threshold Dose dependent |
50–200 | Tomić et al 2010114 | ||||
Writhing test | Acetic acid | Tween 80 and saline | Rat/M | Decreased behavior Dose dependent | 60–180 | |||||||
25. | Synergy between ibuprofen, APAP and codeine | Tail flick | Rat tail Ischaemia | DMSO and saline | Rat/M | Increased threshold Dose dependent |
11–88 | Mitchell et al 2010115 | ||||
26. | TRPV1 in brain is involved in APAP- antinociception | Formalin test Hot plate Von Frey | FAAH and TRPV1 knockout mice | 10% DMSO/2.5% Tween 80/Saline | Mice/M | Decreased behavior Increased latency/threshold |
200 | Mallet et al 201073 | ||||
Formalin test Hot plate Von Frey | FAAH and TRPV1 knockout mice | 10% DMSO/2.5% Tween 80/Saline | Mice/M | Decreased behavior Increased latency/threshold |
100 | |||||||
Active movement | FAAH and TRPV1 knockout mice | 10% DMSO/2.5% Tween 80/Saline | Mice/M | Decreased behavior Dose dependent |
100–300 | |||||||
27. | Modulation of APAP and nefopam antinociception by 5-HT(3) receptor | Formalin test | Formalin | 1% solution of Tween 80 | Mice/M | Decreased behavior | 400 | Girard et al 2009161 | ||||
28. | Synergy between rilmenidine/APAP | Writhing test | Acetic acid | Saline | Mice/M | Decreased behavior Dose dependent |
127–445 | Soukupová et al 200993 | ||||
29. | Differential effects of APAP LPS induced hyperalgesia in various mouse pain models | Formalin test | Formalin | 20% DMSO | Mice/M | Decreased behavior Phase 1/2 Dose dependent |
25–300 | Seo et al 2008146 | ||||
Formalin test | Formalin | 20% DMSO | Mice/M | Decreased behavior Dose dependent |
25–100 | |||||||
Formalin test | Formalin | 20% DMSO | Mice/M | No effect | 25–100 | |||||||
30. | Different mechanisms for APAP and dipyrone | Von Frey | Carrag hindpaw | Saline | Rat/M | Increased threshold | 60–360 | Rezende et al 2008124 | ||||
31. | CB and 5HT systems needed for APAP-analgesia | Formalin test | Formalin | DMSO and saline | Rat/M | Decreased behavior Phase 1/2. |
300 | Mallet et al 200895 | ||||
35 | APAP prevents hyperalgesia in central pain cascade | Hot plate | Spinal substance P | 5% DMSO | Rat/M | Normalized threshold | 300 | Crawley et al 200874 | ||||
Hot plate | Spinal substance P | 5% DMSO | Rat/M | Increased latency Dose dependent |
10–200 | |||||||
32. | Morphine and ABT-594 (a nicotinic acetylcholine agonist) exert central analgesia | Abnormal postures and eye closure) | Cyclophosphamide to induce bladder inflammation | N/A | Rat/M | No change | 44–480 | Joshi et al 200875 | ||||
33. | Different mechanisms underlie actions of APAP and dipyrone | Paw pressure | Carrag hindpaw | Saline | Mice/M | Increased threshold | 60–360 | Rezende et al 2008124 | ||||
34. | Isobolographic interactions between ketoprofen and APAP | Writhing test | Acetic acid | 0.5% carboxymethylcellulose | Mice/M | Decreased behavior Dose dependent |
ED 50 = 129 mg/kg | Qiu et al 200794 | ||||
35. | Orofacial formalin test in the mouse: a behavioral model for studying physiology and modulation of trigeminal pain | Formalin test | Formalin | Saline | Rat/M | Decreased behavior Dose dependent |
25–200 | Luccarini et al 2006125 | ||||
36. | Analgesic effects of nonsteroidal anti-inflammatory drugs, APAP, and morphine | Von Frey | Bone cancer pain model | Methylcellulose 0.5% solution | Mice/M | Increased threshold | 300 | Saito et al 200578 | ||||
37. | Spinal 5-HT1A influence nociceptive processing and effects of APAP, venlafaxine | Formalin test Paw pressure | IT administration of substance P | Saline containing 0.02 g/mL trisodium citrate | Rat/M | Decreased behavior Normalized threshold |
50–300 | Bonnefont et al 2005149 | ||||
38. | Effect of aspirin and APAP on proinfl ammatory cytokine-induced pain | Scratch biting episodes | IT TNF-α, IL-β or IFN-γ | 20% DMSO | Mice/M | Decreased behavior Dose dependent |
100–300 | Kwon et al 200579 | ||||
39. | IPLT APAP does not act locally | Formalin test | Formalin | Saline | Rat/M | Decreased behavior phase 1 | 10–20 (IPLT) | Bonnefont et al 200382 | ||||
Formalin test | Formalin | Saline | Rat/M | Decreased behavior phase 1/2 Dose dependent |
100–400 | |||||||
Formalin test | Formalin | Saline | Rat/M | Decreased behavior Phase 1/2 Dose dependent |
100–300 | |||||||
Formalin test | Formalin | Saline | Rat/M | Decreased behavior Phase 2 |
200 | |||||||
40. | Time course of progression of allodynia and efficacy of analgesics | Von Frey Hot plate Vocal | Freund’s adjuvant | Suspended in 0.5% methylcellulose | Rat/M | No change | 100–600 | Nagakura et al 200383 | ||||
41. | APAP exerts a spinal, tropisetron-reversible effect | Von Frey | Carrag treated | Trisodic citrate, propacetamol | Rat/M | Normalized threshold Dose -dependent | 100–300 | Alloui et al 2002143 | ||||
Von Frey | Carrag treated | Trisodic citrate, propacetamol | Rat/M | Normalized threshold Dose dependent | 50–200 | |||||||
42. | Antinociceptive profiles of aspirin and APAP in formalin, substance P and glutamate pain models | Formalin test | Formalin | 20% DMSO | Mice/M | Decreased behavior Dose dependent |
10–300 | Choi et al 200185 | ||||
Licking/biting | Intrathecal Substance P Glutamate pain | 20% DMSO | Mice/M | Decreased behavior Dose dependent |
10–300 | |||||||
43. | Antinociceptive synergy between spinal APAP and phentolamine | Abdominal irritant test | IP acetylcholine bromide | 5% ethanol/water | Mice/M | Decreased behavior | 137 | Raffa et al 2001144 | ||||
44. | “Self-synergistic” spinal/supraspinal antinociception produced by APAP | Abdominal irritant test | Injected IP with acetylcholine bromide | 5% ethanol/water | Mice/M | Decreased behavior | 137 | Raffa et al 2000154 | ||||
Abdominal irritant test | Injected IP with acetylcholine bromide | 5% ethanol/water | Mice/M | Decreased behavior | 45–150 | |||||||
45. | Phenacetin, APAP and dipyrone: analgesic and rewarding effects | Formalin test | Formalin | Ethanol/water/10% Tween | Rat/M | Decreased behavior Phase 2 Dose dependent |
25–400, | Abbott and Hellemans 2000126 | ||||
Formalin test | Formalin | Ethanol/water/10% Tween | Rat/M | Decreased behavior, low > high dose | 5–100 µg (IPLT) | |||||||
Formalin test | Formalin | Ethanol/water/10% Tween | Rat/M | Decreased behavior, phase 2 No dose dependency |
3–50 | |||||||
46. | NitroAPAP exhibits anti-inflammatory and anti-nociceptive activity | Von Frey | Carrag hind paw | Saline | Mice/M | Normalized threshold Dose -dependent |
25–100 | Al-Swayeh et al 200086 | ||||
Abdominal irritant test | Acetic acid induced abdominal constrict | Saline | Mice/M | Normalized behavior Dose dependent |
25–100 | |||||||
47. | Potentiation of APAP plus morphine involves 5-HT system | Formalin test | Formalin | 12.5% of 1,2-propanediol in saline | Rat/M | Decreased behavior Phase 1/2 | 100 | Sandrini et al 1999118 | ||||
48. | APAP is associated with changes in the serotonergic system in the rat brain | Formalin test | Formalin | 12.5% of 1,2-propanediol in saline | Rat/M | Decreased behavior | 200–400 | Pini et al 1996128 | ||||
49. | The dose-related effects of APAP on hyperalgesia and nociception in the rat | Von Frey Paw pressure | IPLT Brewer’s yeast | 0.25% methocel in 0.9% NaCl | Rat/M | Normalized threshold Dose dependent |
25–100 | Bianchi et al 199696 | ||||
50. | Central antinociceptive effects of non-steroidal anti-inflammatory drugs and APAP | Biting, scratch licking | Intrathecal SP, NMDA, AMPA | Saline | Rat/M | Decreased behavior | 0.01–10 | Björkman 1995129 | ||||
51. | APAP blocks spinal hyperalgesia induced by NMDA and substance P | Biting, scratch licking | Intrathecal SP, NMDA, AMPA | Saline | Rat/M | Decreased behavior | 200 | Björkman et al 1994130 | ||||
52. | Morphine, nefopam and APAP | Formalin test | Formalin | 12.5% of 1,2-propane- diol in 0.9% sterile saline | Rat/N/A (Naked mole rat) | Decreased behavior Phase 2, not phase 1 |
200–400 | Kanui et al 1993131 | ||||
53. | Intrathecal APAP on visceral noxious stimulation in rabbits | Visceral | Colonic distension Cutaneous electrical |
N/R | Rabbit/M | Colonic: increased thresholds Electrical increased threshold Dose dependent |
0.5–5 mg | Jensen et al 1992145 | ||||
Visceral | Colonic distension | N/R | Rabbit/M | Colonic No change Electrical No change |
10–50 | |||||||
54. | APAP plasma levels and analgesic effect | Impairment | Joint uric acid | Saline | Rat/M | Increased threshold Dose dependent |
178–562 | Granados-sato et al 199288 | ||||
55. | Spinal nonsteroidal anti-inflammatory agents | Formalin test | Formalin | 5% ethanol/distilled water | Rat/M | Decreased behavior (phase 2) Dose dependent |
163–405 | Malmberg and Yaksh 1992132 | ||||
56. | Anti-inflammatory effects of a low dose of APAP following surgery | Applied pressure | Postoperative pain | NA | Dog/M and M | Normalized threshold | 500 | Mburu 199197 | ||||
57. | APAP effect is partly dependent on spinal 5-HT systems | Formalin test | Formalin | 5% ethanol/distilled water | Rat/M | Normalized behavior | 400 | Tjølsen et al 1991133 | ||||
58. | Acetylsalicylic acid, APAP and morphine inhibit behavioural responses to substance P or capsaicin | Biting, licking and scratch | Intrathecal SubsP/Capsaicin | 12.5% 1,2-propanediol/saline | Mice/M | Decreased behavior Dose dependent |
300–400 | Hunskaar et al 1985136 | ||||
59. | Aspirin, mefenamic acid, dihydrocodeine, dextropropoxyphene and APAP on respiration and prostaglandin biosynthesis | Writhing test | Acetic acid | 1% tragacanth and saline | Rat/M | Decreased behavior | 213 | Sewell et al 198499 | ||||
60. | Analgesic drugs in chronic inflammatory pain: possible central analgesic action of NSAIDs | Electrical stimulus Vocalize |
Heat-killed adjuvant | Saline | Rat/M | Increased threshold Dose dependent |
50–400 | 25–400 | Okuyama and Aihara 198489 | |||
Electrical stimulus Vocalize |
Heat-killed adjuvant | Saline | Rat/M | Increased threshold Dose dependent |
25–400 | |||||||
61. | Aspirin/APAP on naloxone potency induced by morphine | Writhing test | Acetic acid | Saline | Mice/M | Decreased behavior | 10 or 20 | Wong et al 1980160 | ||||
62. | Butorphanol and APAP combination | Writhing test | Acetic acid | Saline | Mice/M | Decreased behavior Dose dependent |
137–171 | Pircio et al 1978100 | ||||
63. | Central/peripheral action of aspirin-like drugs | Paw pressure | Carrag Hind paw | Saline | Mice/M | Increased threshold Dose dependent |
100–400 | Ferreira et al 1978135 | ||||
Paw pressure | Carrag Hind paw | Saline | Mice/M | Increased threshold Dose dependent |
50–400 μg (IPLT) | |||||||
Paw pressure | Carrag Hind paw | Saline | Mice/M | Increased threshold Dose dependent |
50–400 µg |
|||||||
64. | Comparison of analgesic and anti-inflammatory activities of aspirin, phenacetin and APAP in rodents | Paw pressure | IPLT Trypsin Hind paw | N/A | Rat/NA | No change | ED 50 > 360 mg/kg | Vinegar et al 1976102 | ||||
Paw pressure | IPLT Kaolin Hind paw | N/A | Rat/NA | Increased threshold Dose dependent |
ED 50 = 305 mg/kg | |||||||
Paw pressure | IPLT Carrag Hind paw | N/A | Rat/NA | Increased threshold Dose dependent |
ED 50 = 110 mg/kg | |||||||
Paw pressure | Acetic acid | N/A | Rat/NA | Increased threshold Dose dependent |
ED 50: = 305 mg/kg |